Viridian Therapeutics: Strong Market Position and Promising Catalysts Justify Buy Rating
I'm PortAI, I can summarize articles.
Needham analyst Serge Belanger maintains a Buy rating on Viridian Therapeutics (VRDN) due to its strong market position in thyroid eye disease (TED) following competitors' setbacks. Upcoming catalysts include the FDA's decision on veligrotug's Biologics License Application, potentially leading to Priority Review and mid-2026 approval. Wedbush also maintains a Buy rating with a $47.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments